JP2016508134A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016508134A5 JP2016508134A5 JP2015549669A JP2015549669A JP2016508134A5 JP 2016508134 A5 JP2016508134 A5 JP 2016508134A5 JP 2015549669 A JP2015549669 A JP 2015549669A JP 2015549669 A JP2015549669 A JP 2015549669A JP 2016508134 A5 JP2016508134 A5 JP 2016508134A5
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- pharmaceutical composition
- pharmaceutically acceptable
- composition according
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000031886 HIV Infections Diseases 0.000 claims 4
- 208000037357 HIV infectious disease Diseases 0.000 claims 4
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 102100034343 Integrase Human genes 0.000 claims 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 claims 1
- 229940124411 anti-hiv antiviral agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000004030 hiv protease inhibitor Substances 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- SOLUWJRYJLAZCX-LYOVBCGYSA-N OC1=C(C(N2[C@@H](C3)O[C@H]4C[C@@H]2CC4)=O)N3C=C(C(NCc(c(F)cc(F)c2)c2F)=O)C1=O Chemical compound OC1=C(C(N2[C@@H](C3)O[C@H]4C[C@@H]2CC4)=O)N3C=C(C(NCc(c(F)cc(F)c2)c2F)=O)C1=O SOLUWJRYJLAZCX-LYOVBCGYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261745375P | 2012-12-21 | 2012-12-21 | |
| US61/745,375 | 2012-12-21 | ||
| US201361788397P | 2013-03-15 | 2013-03-15 | |
| US61/788,397 | 2013-03-15 | ||
| US201361845803P | 2013-07-12 | 2013-07-12 | |
| US61/845,803 | 2013-07-12 | ||
| PCT/US2013/076367 WO2014100323A1 (en) | 2012-12-21 | 2013-12-19 | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016122743A Division JP6411409B2 (ja) | 2012-12-21 | 2016-06-21 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016508134A JP2016508134A (ja) | 2016-03-17 |
| JP2016508134A5 true JP2016508134A5 (OSRAM) | 2016-08-12 |
| JP6028105B2 JP6028105B2 (ja) | 2016-11-16 |
Family
ID=49917297
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015549669A Active JP6028105B2 (ja) | 2012-12-21 | 2013-12-19 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
| JP2016122743A Active JP6411409B2 (ja) | 2012-12-21 | 2016-06-21 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
| JP2018179844A Active JP6571256B2 (ja) | 2012-12-21 | 2018-09-26 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
| JP2019145317A Active JP6933690B2 (ja) | 2012-12-21 | 2019-08-07 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
| JP2021134172A Active JP7301918B2 (ja) | 2012-12-21 | 2021-08-19 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
| JP2023101636A Pending JP2023134483A (ja) | 2012-12-21 | 2023-06-21 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
| JP2025093154A Pending JP2025138660A (ja) | 2012-12-21 | 2025-06-04 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016122743A Active JP6411409B2 (ja) | 2012-12-21 | 2016-06-21 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
| JP2018179844A Active JP6571256B2 (ja) | 2012-12-21 | 2018-09-26 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
| JP2019145317A Active JP6933690B2 (ja) | 2012-12-21 | 2019-08-07 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
| JP2021134172A Active JP7301918B2 (ja) | 2012-12-21 | 2021-08-19 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
| JP2023101636A Pending JP2023134483A (ja) | 2012-12-21 | 2023-06-21 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
| JP2025093154A Pending JP2025138660A (ja) | 2012-12-21 | 2025-06-04 | 多環式カルバモイルピリドン化合物およびその薬学的用途 |
Country Status (41)
Families Citing this family (178)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2729448E (pt) | 2011-07-06 | 2015-12-02 | Gilead Sciences Inc | Compostos para o tratamento de vih |
| TWI572605B (zh) | 2012-04-26 | 2017-03-01 | 必治妥美雅史谷比公司 | 血小板聚集之抑制劑 |
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| DK3067358T3 (da) | 2012-12-21 | 2019-11-04 | Gilead Sciences Inc | Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse |
| UA111305C2 (uk) | 2012-12-21 | 2016-04-11 | Пфайзер Інк. | Конденсовані лактами арилу та гетероарилу |
| JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
| LT2945939T (lt) | 2013-01-15 | 2020-07-27 | Incyte Holdings Corporation | Triazolkarboksamidai ir piridinkarboksamido junginiai, naudotini kaip pim kinazės inhibitoriai |
| NO2865735T3 (OSRAM) | 2013-07-12 | 2018-07-21 | ||
| PL3019503T3 (pl) | 2013-07-12 | 2018-01-31 | Gilead Sciences Inc | Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv |
| EP3036238A1 (en) | 2013-08-23 | 2016-06-29 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
| ZA201503540B (en) * | 2014-05-20 | 2016-10-26 | Cipla Ltd | Process for preparing polycyclic carbamoyl pyridone derivatives |
| MY185765A (en) | 2014-06-17 | 2021-06-06 | Pfizer | Substituted dihydroisoquinolinone compounds |
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI744723B (zh) * | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| NO2717902T3 (OSRAM) * | 2014-06-20 | 2018-06-23 | ||
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| WO2016027879A1 (ja) | 2014-08-22 | 2016-02-25 | 塩野義製薬株式会社 | インテグラーゼ阻害活性を有する多環性ピリドン誘導体 |
| WO2016036759A1 (en) | 2014-09-04 | 2016-03-10 | Gilead Sciences, Inc. | Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir |
| WO2016090545A1 (en) * | 2014-12-09 | 2016-06-16 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrate inhibitors |
| TWI695003B (zh) * | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| SG11201705192PA (en) | 2014-12-24 | 2017-07-28 | Gilead Sciences Inc | Fused pyrimidine compounds for the treatment of hiv |
| ES2705709T3 (es) | 2014-12-24 | 2019-03-26 | Gilead Sciences Inc | Compuestos de isoquinolina para el tratamiento del VIH |
| TWI770552B (zh) | 2014-12-24 | 2022-07-11 | 美商基利科學股份有限公司 | 喹唑啉化合物 |
| SG11201705069YA (en) | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| AU2016216673B2 (en) | 2015-03-04 | 2017-02-02 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| EP3277691B1 (en) * | 2015-04-02 | 2019-01-30 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| AU2016256125B9 (en) * | 2015-04-28 | 2020-02-20 | Shionogi And Co., Ltd. | Substituted polycyclic pyridone derivative and prodrug thereof |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| US20210292327A1 (en) | 2015-08-26 | 2021-09-23 | Gilead Sciences, Inc. | Deuterated toll-like receptor modulators |
| AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
| JP2018529714A (ja) | 2015-09-30 | 2018-10-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖの処置のための化合物および組合せ物 |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| BR102016026127A2 (pt) | 2015-11-09 | 2017-05-16 | Gilead Sciences Inc | composições terapêuticas para o tratamento do vírus da imunodeficiência humana |
| EA201891186A1 (ru) | 2015-12-15 | 2018-12-28 | Джилид Сайэнс, Инк. | Антитела, нейтрализующие вирус иммунодефицита человека |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| WO2017197036A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP4299133A3 (en) * | 2016-06-23 | 2024-03-13 | VIIV Healthcare Company | Compositions and methods for the delivery of therapeutics |
| WO2018005328A1 (en) * | 2016-06-27 | 2018-01-04 | Concert Pharmaceuticals, Inc. | Deuterated bictegravir |
| JP6716785B2 (ja) | 2016-08-19 | 2020-07-01 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖウイルス感染症の予防的または治療的処置に有用な治療用化合物 |
| WO2018042331A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| WO2018042332A1 (en) | 2016-08-31 | 2018-03-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Combinations and uses and treatments thereof |
| AU2017318601B2 (en) | 2016-09-02 | 2020-09-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| WO2018051250A1 (en) | 2016-09-14 | 2018-03-22 | Viiv Healthcare Company | Combination comprising tenofovir alafenamide, bictegravir and 3tc |
| WO2018064071A1 (en) | 2016-09-27 | 2018-04-05 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
| ES2992772T3 (en) | 2016-09-28 | 2024-12-18 | Gilead Sciences Inc | Benzothiazol-6-yl acetic acid derivatives and their use for treating hiv infection |
| EP3532478B1 (en) | 2016-10-27 | 2021-05-26 | Gilead Sciences, Inc. | Crystalline form of darunavir free base |
| JOP20190130A1 (ar) | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| CN108250215B (zh) * | 2016-12-28 | 2022-04-19 | 华创合成制药股份有限公司 | 一种新型抗hiv药物及其制备方法和用途 |
| TW202510891A (zh) | 2017-01-31 | 2025-03-16 | 美商基利科學股份有限公司 | 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型 |
| JOP20180009A1 (ar) | 2017-02-06 | 2019-01-30 | Gilead Sciences Inc | مركبات مثبط فيروس hiv |
| CN106860464A (zh) * | 2017-02-16 | 2017-06-20 | 江苏艾迪药业有限公司 | 用于联合抗病毒治疗的药物组合物及应用 |
| CN106860414B (zh) * | 2017-02-16 | 2019-12-24 | 江苏艾迪药业股份有限公司 | 一种用于抗hiv的复方制剂及其制备方法与应用 |
| ZA201803942B (en) | 2017-06-13 | 2021-05-26 | Cipla Ltd | Novel processes for preparation of integrase inhibitor |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| US10882907B2 (en) | 2017-06-21 | 2021-01-05 | Gilead Sciences, Inc. | Multispecific antibodies that target HIV GP120 and CD3 |
| JP7287906B2 (ja) | 2017-06-30 | 2023-06-06 | ヴィーブ ヘルスケア カンパニー | 組み合わせ並びにその使用及びそれによる治療 |
| ES2892402T3 (es) | 2017-08-01 | 2022-02-04 | Gilead Sciences Inc | Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales |
| US20200171039A1 (en) * | 2017-08-09 | 2020-06-04 | Viiv Healthcare Company | Combinations and uses and treatments |
| US20200246351A1 (en) | 2017-08-09 | 2020-08-06 | Viiv Healthcare Company | Combinations and uses and treatments thereof |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| MX2020003469A (es) * | 2017-10-06 | 2020-08-03 | Shionogi & Co | Proceso estereoselectivo para preparar derivados de piridona policiclicos sustituidos. |
| JOP20180092A1 (ar) | 2017-10-13 | 2019-04-13 | Gilead Sciences Inc | مثبطات hiv بروتياز |
| EP3700573A1 (en) | 2017-10-24 | 2020-09-02 | Gilead Sciences, Inc. | Methods of treating patients co-infected with a virus and tuberculosis |
| PL3706762T3 (pl) | 2017-12-07 | 2025-02-10 | Emory University | N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| KR102497051B1 (ko) * | 2018-01-19 | 2023-02-09 | 길리애드 사이언시즈, 인코포레이티드 | 빅테그라비르의 대사물 |
| EP3749673B1 (en) | 2018-02-09 | 2022-03-16 | Sandoz AG | Crystalline form of bictegravir sodium |
| ES2958828T3 (es) | 2018-02-15 | 2024-02-15 | Gilead Sciences Inc | Derivados de piridina y su uso para tratar una infección por VIH |
| PL3752496T3 (pl) | 2018-02-16 | 2023-11-27 | Gilead Sciences, Inc. | Sposoby i związki pośrednie do wytwarzania związku terapeutycznego przydatnego w leczeniu infekcji wirusowej retroviridae |
| WO2019159199A1 (en) | 2018-02-16 | 2019-08-22 | Cipla Limited | Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| CN109020911B (zh) * | 2018-04-16 | 2022-06-28 | 常州制药厂有限公司 | 用于制备bictegravir的中间体及其制备方法 |
| WO2019207602A1 (en) | 2018-04-26 | 2019-10-31 | Mylan Laboratories Limited | Polymorphic forms of bictegravir and its sodium salt |
| US20190359645A1 (en) | 2018-05-03 | 2019-11-28 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide |
| CN110526930B (zh) * | 2018-05-23 | 2022-06-03 | 莫云芬 | 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用 |
| SG11202011386QA (en) | 2018-05-31 | 2020-12-30 | Shionogi & Co | Polycyclic pyridone derivative |
| EP4257137A3 (en) | 2018-05-31 | 2023-11-01 | Shionogi & Co., Ltd | Polycyclic carbamoylpyridone derivatives for the treatment of hiv |
| EP3815689A4 (en) | 2018-06-27 | 2022-04-20 | National University Corporation Hokkaido University | ARENAVIRUS GROWTH INHIBITOR COMPRISING A POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE |
| WO2020003151A1 (en) | 2018-06-28 | 2020-01-02 | Honour Lab Limited | Process for the preparation of sodium (2r,5s,13ar)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1', 2':4,5]pyrazino[2,1-b] [1,3] oxazepin-8-olate and its polymorphic form |
| PE20210685A1 (es) | 2018-07-03 | 2021-04-08 | Gilead Sciences Inc | Anticuerpos que se dirigen al gp120 de vih y metodos de uso |
| WO2020012408A2 (en) * | 2018-07-12 | 2020-01-16 | Laurus Labs Limited | A process for purification of protected polycyclic carbamoylpyridone derivatives |
| CN120078775A (zh) | 2018-07-16 | 2025-06-03 | 吉利德科学公司 | 用于治疗hiv的衣壳抑制剂 |
| TWI766172B (zh) | 2018-07-30 | 2022-06-01 | 美商基利科學股份有限公司 | 抗hiv化合物 |
| CA3113011A1 (en) | 2018-09-19 | 2020-03-26 | Gilead Sciences, Inc. | Integrase inhibitors for the prevention of hiv |
| EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| WO2020086555A1 (en) * | 2018-10-22 | 2020-04-30 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and nanoformulations thereof |
| CN117105933A (zh) | 2018-10-31 | 2023-11-24 | 吉利德科学公司 | 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物 |
| MX2021005047A (es) | 2018-10-31 | 2021-09-08 | Gilead Sciences Inc | Compuestos de 6-azabenzimidazol sustituidos como inhibidores de hpk1. |
| EP3653629A1 (en) * | 2018-11-16 | 2020-05-20 | Sandoz AG | Acid addition salts of an integrase strand transfer inhibitor |
| US20220175936A1 (en) | 2018-11-29 | 2022-06-09 | Board Of Regents Of The University Of Nebraska | Antiviral prodrugs and nanoformulations thereof |
| US12195480B2 (en) | 2019-02-07 | 2025-01-14 | Cipla Limited | Polymorphs of integrase inhibitor |
| WO2020176510A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
| WO2020176505A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
| AU2020231115B2 (en) | 2019-03-07 | 2025-02-20 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| DK3934757T3 (da) | 2019-03-07 | 2023-04-17 | Inst Of Organic Chemistry And Biochemistry Ascr V V I | 2'3'-cykliske dinukleotider og prodrugs deraf |
| WO2020197991A1 (en) * | 2019-03-22 | 2020-10-01 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US20200347036A1 (en) | 2019-04-17 | 2020-11-05 | Gilead Sciences, Inc. | Solid forms of an hiv protease inhibitor |
| TW202104210A (zh) | 2019-04-17 | 2021-02-01 | 美商基利科學股份有限公司 | Hiv蛋白酶抑制劑 |
| TW202231277A (zh) | 2019-05-21 | 2022-08-16 | 美商基利科學股份有限公司 | 鑑別對使用gp120 v3聚醣導向之抗體的治療敏感之hiv病患的方法 |
| CN110229174A (zh) * | 2019-05-22 | 2019-09-13 | 博诺康源(北京)药业科技有限公司 | Bictegravir原料药基因毒性杂质的合成方法 |
| TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
| RU2717101C1 (ru) * | 2019-06-03 | 2020-03-18 | Андрей Александрович Иващенко | Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения |
| CN110263404B (zh) * | 2019-06-12 | 2023-03-21 | 江苏大学 | 一种基于dpm模型的一体化预制泵站沉积特性的计算方法 |
| US12486286B2 (en) * | 2019-06-18 | 2025-12-02 | Laurus Labs Limited | Process and polymorphic forms of bictegravir and its pharmaceutically acceptable salts or co-crystals thereof |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
| PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
| US11248005B2 (en) | 2019-07-08 | 2022-02-15 | Lupin Limited | Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| US20220296619A1 (en) | 2019-08-19 | 2022-09-22 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN110698473B (zh) * | 2019-10-08 | 2020-12-18 | 浙江大学 | 哌嗪酮并羟基吡啶酮-5-羧基类化合物及制备和应用 |
| AU2020391466B2 (en) | 2019-11-26 | 2024-05-23 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
| JP7776335B2 (ja) * | 2019-11-28 | 2025-11-26 | 塩野義製薬株式会社 | 多環性ピリドピラジン誘導体 |
| EP4066839A4 (en) | 2019-11-28 | 2023-12-27 | Shionogi & Co., Ltd | PROPHYLACTIC AND THERAPEUTIC MEDICINAL PRODUCT FOR HIV INFECTIOUS DISEASES, CHARACTERIZED BY CONTAINING THE COMBINATION OF INTEGRAS INHIBITORS AND ANTI-HIV AGENTS |
| MX2022007930A (es) | 2019-12-24 | 2022-08-08 | Carna Biosciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| IL295677A (en) | 2020-02-24 | 2022-10-01 | Gilead Sciences Inc | Tetracyclic compounds for treating hiv infection |
| AR121620A1 (es) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | Profármacos de nucleósidos 4-c-sustituidos-2-halo-2-deoxiadenosina y métodos de preparación y uso de los mismos |
| WO2021236944A1 (en) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| CN113698420A (zh) * | 2020-05-22 | 2021-11-26 | 上海迪赛诺生物医药有限公司 | 比克替拉韦钠的新晶型及其制备方法 |
| CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
| US12110305B2 (en) | 2020-08-07 | 2024-10-08 | Gilead Sciences, Inc. | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| US12421235B2 (en) * | 2020-09-30 | 2025-09-23 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| CN114426540B (zh) * | 2020-10-29 | 2024-04-26 | 上海拓界生物医药科技有限公司 | 吡啶并[1,2-a]吡嗪-1,8-二酮类前药衍生物、其制备方法及其应用 |
| TW202227445A (zh) * | 2020-10-30 | 2022-07-16 | 大陸商上海拓界生物醫藥科技有限公司 | 抑制基因缺陷的ｈｉｖ病毒的用途 |
| PT4244396T (pt) | 2020-11-11 | 2025-10-20 | Gilead Sciences Inc | Métodos de identificação de doentes com hiv sensíveis à terapia com anticorpos dirigidos ao sítio de ligação cd4 da gp120 |
| PT4196479T (pt) | 2021-01-19 | 2024-01-03 | Gilead Sciences Inc | Compostos de piridotriazinas substituídos e suas utilizações |
| EP4281076A4 (en) * | 2021-01-22 | 2024-07-31 | Laurus Labs Limited | Processes for purification of bictegravir intermediates |
| CN114835730A (zh) * | 2021-02-02 | 2022-08-02 | 齐鲁制药有限公司 | 一种制备多环氨基甲酰基吡啶酮化合物的方法 |
| WO2022224120A1 (en) | 2021-04-19 | 2022-10-27 | Honour Lab Limited | Polymorphic forms of bictegravir potassium |
| US20220389394A1 (en) | 2021-05-18 | 2022-12-08 | Gilead Sciences, Inc. | METHODS OF USING FLT3L-Fc FUSION PROTEINS |
| WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| JP7686086B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリエルコール（ｄｉａｃｙｌｇｌｙｅｒｃｏｌ）キナーゼ調節化合物 |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117751118A (zh) * | 2021-07-30 | 2024-03-22 | 吉斯凯(苏州)制药有限公司 | 大环吡啶酮类化合物及其应用 |
| CN114230579A (zh) * | 2021-11-12 | 2022-03-25 | 南京艾迪医药科技有限公司 | 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物 |
| WO2023102529A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| PL4445900T3 (pl) | 2021-12-03 | 2025-09-22 | Gilead Sciences, Inc. | Związki terapeutyczne przeciwko zakażeniu wirusem hiv |
| WO2023102523A1 (en) | 2021-12-03 | 2023-06-08 | Gilead Sciences, Inc. | Therapeutic compounds for hiv virus infection |
| CN114605437A (zh) * | 2022-04-01 | 2022-06-10 | 遵义医科大学 | 连续一锅法制备三个替拉韦药物的合成工艺 |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
| WO2023248240A1 (en) | 2022-06-21 | 2023-12-28 | Mylan Laboratories Limited | Polymorphic forms of bictegravir sodium |
| TW202434566A (zh) | 2022-07-01 | 2024-09-01 | 美商基利科學股份有限公司 | 可用於hiv病毒感染之疾病預防性或治療性治療的治療性化合物 |
| CN119677546A (zh) | 2022-07-12 | 2025-03-21 | 吉利德科学公司 | Hiv免疫原性多肽和疫苗及其用途 |
| CA3265134A1 (en) | 2022-08-26 | 2024-02-29 | Gilead Sciences Inc | DOSING AND PLANNING REGIMEN FOR BROADLY NEUTRALIZING ANTIBODIES |
| WO2024061257A1 (zh) * | 2022-09-20 | 2024-03-28 | 吉斯凯(苏州)制药有限公司 | 多环氮杂环酮类化合物及其应用 |
| EP4598934A1 (en) | 2022-10-04 | 2025-08-13 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| AU2024259111A1 (en) | 2023-04-19 | 2025-10-16 | Gilead Sciences, Inc. | Dosing regimen of capsid inhibitor |
| US20250011352A1 (en) | 2023-05-31 | 2025-01-09 | Gilead Sciences, Inc. | Solid forms |
| TW202448483A (zh) | 2023-05-31 | 2024-12-16 | 美商基利科學股份有限公司 | 用於ｈｉｖ之治療性化合物 |
| US20250051375A1 (en) | 2023-05-31 | 2025-02-13 | Gilead Sciences, Inc. | Anti-hiv compounds |
| WO2025029247A1 (en) | 2023-07-28 | 2025-02-06 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| EP4529922A1 (en) | 2023-09-29 | 2025-04-02 | Gilead Sciences, Inc. | Pharmaceutical formulations of bictegravir and lenacapavir |
| US20250073172A1 (en) | 2023-08-15 | 2025-03-06 | Gilead Sciences, Inc. | Pharmaceutical formulations of bictegravir and lenacapavir |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| WO2025076542A1 (en) | 2023-10-05 | 2025-04-10 | Jones R Brad | Atovaquone as an ros inducer for use in the elimination of hiv-infected t-cells |
| US20250120989A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250122219A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| US20250127801A1 (en) | 2023-10-11 | 2025-04-24 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025137245A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250289822A1 (en) | 2024-03-01 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| US20250296932A1 (en) | 2024-03-01 | 2025-09-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| WO2025184609A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025212814A1 (en) | 2024-04-03 | 2025-10-09 | Gilead Sciences, Inc. | Anti-hiv compounds |
Family Cites Families (135)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE788516A (fr) | 1971-09-10 | 1973-03-07 | Lonza Ag | Procede de fabrication d'esters alcoxyacetylacetiques |
| GB1528382A (en) | 1974-12-26 | 1978-10-11 | Teijin Ltd | Cyclopentene diols and acyl esters thereof and processes for their preparation |
| DE2658401A1 (de) | 1976-12-23 | 1978-07-06 | Merck Patent Gmbh | Cyclopentan-1-amine, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel |
| US4575694A (en) | 1984-03-05 | 1986-03-11 | Allied Corporation | Coaxial connector |
| DE3900735A1 (de) | 1989-01-12 | 1990-07-26 | Hoechst Ag | Neue mehrfunktionelle (alpha)-diazo-(beta)-ketoester, verfahren zu ihrer herstellung und deren verwendung |
| US5914331A (en) | 1990-02-01 | 1999-06-22 | Emory University | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane |
| US6703396B1 (en) | 1990-02-01 | 2004-03-09 | Emory University | Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers |
| US5204466A (en) | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| DE4014649A1 (de) | 1990-05-08 | 1991-11-14 | Hoechst Ag | Neue mehrfunktionelle verbindungen mit (alpha)-diazo-ss-ketoester- und sulfonsaeureester-einheiten, verfahren zu ihrer herstellung und deren verwendung |
| GB9301000D0 (en) | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| SE9702772D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
| US5935946A (en) | 1997-07-25 | 1999-08-10 | Gilead Sciences, Inc. | Nucleotide analog composition and synthesis method |
| AU1403099A (en) | 1997-11-14 | 1999-06-07 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
| BR9915194A (pt) | 1998-11-09 | 2001-08-07 | Black James Foundation | Composto, método para fabricar o mesmo, composição farmacêutica, e, método para fabricar a mesma |
| GB2345058A (en) | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
| US6620841B1 (en) | 1998-12-25 | 2003-09-16 | Shionogi & Co., Ltd. | Aromatic heterocycle compounds having HIV integrase inhibiting activities |
| AU2001262732A1 (en) | 2000-06-14 | 2001-12-24 | Shionogi And Co., Ltd. | Inhibitor for enzyme having two divalent metal ions as active centers |
| ATE364385T1 (de) * | 2000-10-12 | 2007-07-15 | Merck & Co Inc | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
| EP2181985B1 (en) | 2001-08-10 | 2011-10-26 | Shionogi & Co., Ltd. | Antiviral Agent |
| MY169670A (en) | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| NZ532018A (en) | 2001-10-03 | 2004-12-24 | Ucb S | Pyrrolidinone derivatives |
| CA2463976C (en) | 2001-10-26 | 2007-02-13 | Benedetta Crescenzi | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase |
| WO2004004657A2 (en) | 2002-07-09 | 2004-01-15 | Bristol-Myers Squibb Company | Hiv integrase inhibitors |
| JP2006506352A (ja) | 2002-09-11 | 2006-02-23 | メルク エンド カムパニー インコーポレーテッド | Ｈｉｖインテグラーゼ阻害剤として有用なジヒドロキシピリドピラジン−１，６−ジオン化合物 |
| AR042095A1 (es) | 2002-11-20 | 2005-06-08 | Japan Tobacco Inc | Compuesto 4-oxoquinolina y aplicacion del mismo como inhibidor de integrasa de vih |
| US20040224917A1 (en) | 2003-01-14 | 2004-11-11 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| TW200528440A (en) | 2003-10-31 | 2005-09-01 | Fujisawa Pharmaceutical Co | 2-cyanopyrrolidinecarboxamide compound |
| CN101014571A (zh) | 2004-01-30 | 2007-08-08 | 默克公司 | 用作hiv整合酶抑制剂的n－苄基－3,4－二羟基吡啶－2－羧酰胺类和n－苄基－2,3－二羟基吡啶－4－羧酰胺类化合物 |
| JP4859676B2 (ja) | 2004-02-11 | 2012-01-25 | スミスクライン ビーチャム コーポレーション | Ｈｉｖインテグラーゼ阻害剤 |
| CN101014574A (zh) | 2004-03-09 | 2007-08-08 | 默克公司 | Hiv整合酶抑制剂 |
| WO2005110399A2 (en) | 2004-04-29 | 2005-11-24 | The Regents Of The University Of California | Zinc-binding groups for metalloprotein inhibitors |
| EP1755586A2 (en) | 2004-04-29 | 2007-02-28 | The Regents of the University of California | Hydroxypyridinone, hydroxypyridinethione, pyrone, and thiopyrone metalloprotein inhibitors |
| CN1964975B (zh) | 2004-05-07 | 2011-11-30 | 默沙东公司 | Hiv整合酶抑制剂 |
| US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| CN1953751A (zh) * | 2004-05-17 | 2007-04-25 | 泰博特克药品有限公司 | 取代的1－苯基－1,5－二氢－吡啶并－[3,2－b]吲哚－2－酮和其它的hiv抑制剂的组合物 |
| WO2005113509A1 (en) | 2004-05-20 | 2005-12-01 | Japan Tobacco Inc. | Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor |
| MY134672A (en) | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| WO2005112930A1 (en) | 2004-05-21 | 2005-12-01 | Japan Tobacco Inc. | Combinations comprising a 4-isoquinolone derivative and anti-hiv agents |
| US7550463B2 (en) | 2004-09-15 | 2009-06-23 | Shionogi & Co., Ltd. | Carbamoylpyridone derivatives having inhibitory activity against HIV integrase |
| JP2006118669A (ja) | 2004-10-25 | 2006-05-11 | Sanoh Industrial Co Ltd | 樹脂チューブ |
| WO2006066414A1 (en) | 2004-12-23 | 2006-06-29 | Virochem Pharma Inc. | Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase |
| EP1852434B1 (en) | 2005-02-21 | 2011-07-13 | Shionogi Co., Ltd. | Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity |
| JP4295353B2 (ja) | 2005-04-28 | 2009-07-15 | スミスクライン ビーチャム コーポレーション | Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体 |
| WO2006125048A2 (en) | 2005-05-16 | 2006-11-23 | Gilead Sciences, Inc. | Hiv-integrase inhibitor compounds |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| CA2616314A1 (en) | 2005-07-27 | 2007-02-01 | Gilead Sciences, Inc. | Antiviral phosphonate conjugates for inhibition of hiv |
| JP5131689B2 (ja) | 2005-10-27 | 2013-01-30 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体 |
| SG170796A1 (en) | 2005-12-30 | 2011-05-30 | Gilead Sciences Inc Us | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
| EP2452682A1 (en) | 2006-02-01 | 2012-05-16 | Japan Tobacco, Inc. | Use of 6-(3-chloro-2-fluorobenzyl)-1-[(2s)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or salt thereof for treating retrovirus infection |
| AU2007223260C1 (en) | 2006-03-06 | 2011-02-03 | Japan Tobacco Inc. | Method for producing 4-oxoquinoline compound |
| US8420821B2 (en) | 2006-03-06 | 2013-04-16 | Japan Tobacco Inc. | Process for production of 4-oxoquinoline compound |
| US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| JP2009543865A (ja) | 2006-07-19 | 2009-12-10 | ユニバーシティ オブ ジョージア リサーチ ファウンデーション， インコーポレーテッド | ピリジノンジケト酸：併用療法におけるｈｉｖ複製の阻害剤 |
| MX2009002689A (es) | 2006-09-12 | 2009-03-26 | Gilead Sciences Inc | Proceso e intermediarios para preparar inhibidores de integrasa. |
| US20100216834A1 (en) | 2006-10-18 | 2010-08-26 | Isaacs Richard C A | Hiv integrase inhibitors |
| ES2602784T3 (es) | 2007-02-23 | 2017-02-22 | Gilead Sciences, Inc. | Moduladores de las propiedades farmacocinéticas de los agentes terapéuticos |
| US20080280945A1 (en) | 2007-05-09 | 2008-11-13 | Sachin Lohani | Crystalline forms of an HIV integrase inhibitor |
| EP2167088A1 (en) | 2007-06-29 | 2010-03-31 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| KR20100028656A (ko) | 2007-06-29 | 2010-03-12 | 길리애드 사이언시즈, 인코포레이티드 | 치료 조성물 및 그의 용도 |
| US20090012103A1 (en) | 2007-07-05 | 2009-01-08 | Matthew Abelman | Substituted heterocyclic compounds |
| CA2693340A1 (en) | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Pyrone analog compositions and methods |
| AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| WO2009062285A1 (en) | 2007-11-16 | 2009-05-22 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| GB0803019D0 (en) | 2008-02-19 | 2008-03-26 | Btg Int Ltd | Fluorinated compounds |
| US8129398B2 (en) | 2008-03-19 | 2012-03-06 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US20100272811A1 (en) | 2008-07-23 | 2010-10-28 | Alkermes,Inc. | Complex of trospium and pharmaceutical compositions thereof |
| EP2320909B8 (en) | 2008-07-25 | 2016-03-30 | VIIV Healthcare Company | Chemical compounds |
| WO2010011816A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011818A1 (en) * | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011812A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
| WO2010068262A1 (en) | 2008-12-11 | 2010-06-17 | Glaxosmithkline Llc | Processes and intermediates for carbamoylpyridone hiv integrase inhibitors |
| EP3210603A1 (en) * | 2008-12-11 | 2017-08-30 | Shionogi & Co., Ltd | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
| AU2009333653B2 (en) | 2008-12-17 | 2015-09-10 | Merck Patent Gmbh | C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof |
| EA021313B1 (ru) | 2009-02-06 | 2015-05-29 | Джилид Сайэнс, Инк. | Таблетки для комбинированной терапии |
| WO2010110231A1 (ja) | 2009-03-26 | 2010-09-30 | 塩野義製薬株式会社 | 置換された３－ヒドロキシ－４－ピリドン誘導体 |
| TWI518084B (zh) * | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| PL2444400T3 (pl) | 2009-06-15 | 2018-08-31 | Shionogi & Co., Ltd. | Podstawiona policykliczna pochodna karbamoilopirydonowa |
| WO2011011483A1 (en) * | 2009-07-22 | 2011-01-27 | Glaxosmithkline Llc | Chemical compounds |
| WO2011028044A2 (ko) | 2009-09-02 | 2011-03-10 | 이화여자대학교 산학협력단 | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 |
| NZ627827A (en) | 2010-01-27 | 2016-02-26 | Viiv Healthcare Co | Antiviral combinations involving (3s, 11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide |
| SG183484A1 (en) | 2010-02-26 | 2012-09-27 | Japan Tobacco Inc | 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor |
| TWI582097B (zh) | 2010-03-23 | 2017-05-11 | Ｖｉｉｖ醫療保健公司 | 製備胺甲醯吡啶酮衍生物及中間體之方法 |
| US20130165489A1 (en) | 2010-05-03 | 2013-06-27 | The Trustees Of The University Of Pennsylvania | Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof |
| MA34397B1 (fr) | 2010-07-02 | 2013-07-03 | Gilead Sciences Inc | Dérivés d'acide napht-2-ylacétique dans le traitement du sida |
| WO2012003498A1 (en) | 2010-07-02 | 2012-01-05 | Gilead Sciences, Inc. | 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds |
| WO2012009009A2 (en) | 2010-07-14 | 2012-01-19 | Addex Pharma S.A. | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| EP3127908B1 (en) | 2010-08-05 | 2018-11-28 | Shionogi & Co., Ltd | Process for preparing compound having hiv integrase inhibitory activity |
| HRP20181250T1 (hr) | 2010-09-24 | 2018-10-05 | Shionogi & Co., Ltd. | Predlijek iz supstituiranog policikličkog derivata karbamoilpiridona |
| ES2524408T5 (es) | 2010-11-19 | 2022-04-25 | Gilead Sciences Inc | Composiciones terapéuticas que comprenden rilpivirina HCl y tenofovir disoproxil fumarato |
| WO2012106534A2 (en) | 2011-02-02 | 2012-08-09 | The Regents Of The University Of California | Hiv integrase inhibitors |
| WO2012145728A1 (en) | 2011-04-21 | 2012-10-26 | Gilead Sciences, Inc. | Benzothiazole compounds and their pharmaceutical use |
| US20140213553A1 (en) | 2011-05-03 | 2014-07-31 | Concert Pharmaceuticals Inc. | Carbamoylpyridone derivatives |
| WO2012151567A1 (en) | 2011-05-05 | 2012-11-08 | St. Jude Children's Research Hospital | Pyrimidinone compounds and methods for preventing and treating influenza |
| US9121496B2 (en) | 2011-06-29 | 2015-09-01 | Arvinmeritor Technology, Llc | Drive axle system and a method of control |
| PT2729448E (pt) | 2011-07-06 | 2015-12-02 | Gilead Sciences Inc | Compostos para o tratamento de vih |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| PL2729130T3 (pl) | 2011-07-07 | 2018-02-28 | Janssen Sciences Ireland Uc | Preparaty kombinowane darunawiru |
| PL2742051T3 (pl) | 2011-09-14 | 2017-06-30 | Mapi Pharma Limited | Amorficzna postać soli sodowej dolutegrawiru |
| EP2774928B1 (en) | 2011-10-12 | 2017-08-30 | Shionogi & Co., Ltd. | Polycyclic pyridone derivative having integrase-inhibiting activity |
| CN104114559B (zh) | 2011-12-12 | 2016-08-24 | 拜耳知识产权有限责任公司 | 氨基取代的咪唑并哒嗪 |
| WO2013103738A1 (en) | 2012-01-04 | 2013-07-11 | Gilead Sciences, Inc. | Napthalene acetic acid derivatives against hiv infection |
| WO2014008636A1 (en) | 2012-07-11 | 2014-01-16 | Merck Sharp & Dohme Corp. | Macrocyclic compounds as hiv integrase inhibitors |
| US20150166520A1 (en) | 2012-07-20 | 2015-06-18 | Merck Sharp & Dohme Corp. | Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection |
| US20150218164A1 (en) | 2012-07-25 | 2015-08-06 | Merck Sharp & Dohme Corp. | Substituted naphthyridinedione derivatives as hiv integrase inhibitors |
| US8877931B2 (en) | 2012-08-03 | 2014-11-04 | Gilead Sciences, Inc. | Process and intermediates for preparing integrase inhibitors |
| SG11201503397YA (en) | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| MA38182A1 (fr) | 2012-12-14 | 2018-04-30 | Glaxosmithkline Llc | Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih) |
| US9714243B2 (en) | 2012-12-17 | 2017-07-25 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as HIV integrase inhibitors |
| DK3067358T3 (da) | 2012-12-21 | 2019-11-04 | Gilead Sciences Inc | Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse |
| US20140221355A1 (en) | 2012-12-21 | 2014-08-07 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| EP2934482A4 (en) | 2012-12-21 | 2016-07-20 | Merck Sharp & Dohme | ADMINISTRATIVE FORMULATIONS |
| SG11201504982PA (en) | 2012-12-27 | 2015-07-30 | Japan Tobacco Inc | SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE AND MEDICINAL USE THEREOF AS HIV INTEGRASE INHIBITOR |
| EP2986291B1 (en) | 2013-04-16 | 2020-05-27 | Merck Sharp & Dohme Corp. | 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors |
| US9951079B2 (en) | 2013-06-13 | 2018-04-24 | Merck Sharp & Dohme Corp. | Fused tricyclic heterocyclic compounds as HIV integrase inhibitors |
| NO2865735T3 (OSRAM) | 2013-07-12 | 2018-07-21 | ||
| PL3019503T3 (pl) | 2013-07-12 | 2018-01-31 | Gilead Sciences Inc | Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv |
| WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
| EP3049081B1 (en) | 2013-09-27 | 2019-11-27 | Merck Sharp & Dohme Corp. | Substituted quinolizine derivatives useful as hiv integrase inhibitors |
| WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
| US9856271B2 (en) | 2014-01-21 | 2018-01-02 | Laurus Labs Limited | Process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof |
| WO2015138933A1 (en) | 2014-03-13 | 2015-09-17 | Assia Chemical Industries Ltd. | Solid state forms of dolutegravir sodium |
| NO2717902T3 (OSRAM) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI744723B (zh) | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| EA201790024A1 (ru) * | 2014-07-11 | 2017-07-31 | Джилид Сайэнс, Инк. | Модуляторы toll-подобных рецепторов для лечения вич |
| TWI695003B (zh) | 2014-12-23 | 2020-06-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| EP3277691B1 (en) | 2015-04-02 | 2019-01-30 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| SI3316868T1 (sl) | 2015-06-30 | 2020-04-30 | Gilead Sciences, Inc. | Farmacevtske formulacije, ki vsebujejo tenofovir in emtricitabin |
| CA2921336A1 (en) | 2015-06-30 | 2016-12-30 | Gilead Sciences, Inc. | Pharmaceutical formulations |
| BR102016026127A2 (pt) | 2015-11-09 | 2017-05-16 | Gilead Sciences Inc | composições terapêuticas para o tratamento do vírus da imunodeficiência humana |
-
2013
- 2013-12-19 DK DK15201519T patent/DK3067358T3/da active
- 2013-12-19 CA CA2893843A patent/CA2893843C/en active Active
- 2013-12-19 US US14/133,858 patent/US9216996B2/en active Active
- 2013-12-19 TW TW107127529A patent/TWI693224B/zh active
- 2013-12-19 CN CN201711080644.6A patent/CN107674086B/zh active Active
- 2013-12-19 TW TW112109785A patent/TWI830624B/zh active
- 2013-12-19 EP EP13815937.1A patent/EP2822954B1/en active Active
- 2013-12-19 MD MDA20150064A patent/MD4736C1/ro active IP Right Grant
- 2013-12-19 TW TW109111537A patent/TWI752457B/zh active
- 2013-12-19 UA UAA201506209A patent/UA114351C2/uk unknown
- 2013-12-19 PL PL15201519T patent/PL3067358T3/pl unknown
- 2013-12-19 KR KR1020217012463A patent/KR102351912B1/ko active Active
- 2013-12-19 PE PE2015001036A patent/PE20151499A1/es active IP Right Grant
- 2013-12-19 WO PCT/US2013/076367 patent/WO2014100323A1/en not_active Ceased
- 2013-12-19 MD MDA20200093A patent/MD4841B1/ro not_active IP Right Cessation
- 2013-12-19 PL PL13815937.1T patent/PL2822954T3/pl unknown
- 2013-12-19 ES ES13815937.1T patent/ES2577283T3/es active Active
- 2013-12-19 HU HUE19185121A patent/HUE059688T2/hu unknown
- 2013-12-19 KR KR1020227001078A patent/KR102406288B1/ko active Active
- 2013-12-19 SI SI201331609T patent/SI3067358T1/sl unknown
- 2013-12-19 EP EP22178867.2A patent/EP4122935A1/en active Pending
- 2013-12-19 PT PT152015194T patent/PT3067358T/pt unknown
- 2013-12-19 MY MYPI2015001580A patent/MY164352A/en unknown
- 2013-12-19 MX MX2018009058A patent/MX372534B/es unknown
- 2013-12-19 PT PT138159371T patent/PT2822954E/pt unknown
- 2013-12-19 HU HUE13815937A patent/HUE028284T2/en unknown
- 2013-12-19 AU AU2013361401A patent/AU2013361401C1/en active Active
- 2013-12-19 CA CA3131094A patent/CA3131094A1/en active Pending
- 2013-12-19 UA UAA201612380A patent/UA123572C2/uk unknown
- 2013-12-19 MD MDA20170067A patent/MD4754C1/ro active IP Right Grant
- 2013-12-19 KR KR1020237014240A patent/KR20230061576A/ko not_active Ceased
- 2013-12-19 ES ES19185121T patent/ES2926068T3/es active Active
- 2013-12-19 KR KR1020157019194A patent/KR101770048B1/ko active Active
- 2013-12-19 SI SI201332004T patent/SI3608325T1/sl unknown
- 2013-12-19 MX MX2015008009A patent/MX344879B/es active IP Right Grant
- 2013-12-19 PT PT191851211T patent/PT3608325T/pt unknown
- 2013-12-19 CR CR20170279A patent/CR20170279A/es unknown
- 2013-12-19 NZ NZ709260A patent/NZ709260A/en unknown
- 2013-12-19 TW TW102147242A patent/TWI642669B/zh active
- 2013-12-19 HR HRP20220899TT patent/HRP20220899T1/hr unknown
- 2013-12-19 EA EA201890236A patent/EA037633B1/ru unknown
- 2013-12-19 EP EP15201519.4A patent/EP3067358B1/en active Active
- 2013-12-19 CN CN201380073134.XA patent/CN104995198B/zh active Active
- 2013-12-19 SI SI201330197A patent/SI2822954T1/sl unknown
- 2013-12-19 TW TW110146626A patent/TWI815245B/zh active
- 2013-12-19 HU HUE15201519A patent/HUE046559T2/hu unknown
- 2013-12-19 KR KR1020207015960A patent/KR102246963B1/ko active Active
- 2013-12-19 KR KR1020197031864A patent/KR102120875B1/ko active Active
- 2013-12-19 LT LT15201519T patent/LT3067358T/lt unknown
- 2013-12-19 MX MX2017000362A patent/MX357940B/es unknown
- 2013-12-19 DK DK19185121.1T patent/DK3608325T3/da active
- 2013-12-19 LT LTEP19185121.1T patent/LT3608325T/lt unknown
- 2013-12-19 PH PH12016500389A patent/PH12016500389A1/en unknown
- 2013-12-19 KR KR1020177016697A patent/KR102040007B1/ko active Active
- 2013-12-19 ME MEP-2016-93A patent/ME02400B/me unknown
- 2013-12-19 ES ES15201519T patent/ES2753548T3/es active Active
- 2013-12-19 UY UY35213A patent/UY35213A/es not_active Application Discontinuation
- 2013-12-19 RS RS20160407A patent/RS54873B1/sr unknown
- 2013-12-19 AR ARP130104930A patent/AR094197A1/es active IP Right Grant
- 2013-12-19 MY MYPI2016001880A patent/MY191741A/en unknown
- 2013-12-19 EA EA201591027A patent/EA030003B1/ru active Protection Beyond IP Right Term
- 2013-12-19 KR KR1020227018650A patent/KR102527797B1/ko active Active
- 2013-12-19 JP JP2015549669A patent/JP6028105B2/ja active Active
- 2013-12-19 DK DK13815937.1T patent/DK2822954T3/en active
- 2013-12-19 EP EP19185121.1A patent/EP3608325B1/en active Active
- 2013-12-19 CA CA3012242A patent/CA3012242C/en active Active
- 2013-12-19 PH PH12019501848A patent/PH12019501848A1/en unknown
- 2013-12-19 SG SG11201504857SA patent/SG11201504857SA/en unknown
- 2013-12-19 BR BR112015014714-3A patent/BR112015014714B1/pt active IP Right Grant
- 2013-12-19 AP AP2015008510A patent/AP2015008510A0/xx unknown
- 2013-12-19 BR BR122015029881-4A patent/BR122015029881B1/pt active IP Right Grant
- 2013-12-19 CN CN202310322212.0A patent/CN116640140A/zh active Pending
- 2013-12-19 PE PE2016000694A patent/PE20170528A1/es unknown
- 2013-12-19 NZ NZ718708A patent/NZ718708A/en unknown
- 2013-12-19 PL PL19185121.1T patent/PL3608325T3/pl unknown
- 2013-12-19 HR HRP20160544TT patent/HRP20160544T1/hr unknown
- 2013-12-19 CN CN202010188107.9A patent/CN111303152B/zh active Active
-
2015
- 2015-06-10 IL IL239316A patent/IL239316A/en active IP Right Grant
- 2015-06-18 MX MX2022013596A patent/MX2022013596A/es unknown
- 2015-06-18 MX MX2020003055A patent/MX2020003055A/es unknown
- 2015-06-18 CL CL2015001756A patent/CL2015001756A1/es unknown
- 2015-06-22 PH PH12015501445A patent/PH12015501445A1/en unknown
- 2015-07-17 CR CR20150380A patent/CR20150380A/es unknown
- 2015-07-31 US US14/815,504 patent/US9663528B2/en active Active
- 2015-10-26 ZA ZA2015/07997A patent/ZA201507997B/en unknown
-
2016
- 2016-04-11 CL CL2016000837A patent/CL2016000837A1/es unknown
- 2016-05-23 IL IL245780A patent/IL245780B/en active IP Right Grant
- 2016-05-30 CY CY20161100472T patent/CY1117570T1/el unknown
- 2016-06-01 SM SM201600157T patent/SMT201600157B/it unknown
- 2016-06-21 JP JP2016122743A patent/JP6411409B2/ja active Active
- 2016-08-17 IL IL247311A patent/IL247311A0/en unknown
- 2016-11-11 US US15/349,934 patent/US9732092B2/en active Active
- 2016-11-24 AU AU2016262722A patent/AU2016262722B2/en active Active
-
2017
- 2017-05-11 CL CL2017001191A patent/CL2017001191A1/es unknown
- 2017-05-18 US US15/599,151 patent/US10035809B2/en active Active
-
2018
- 2018-06-25 US US16/017,371 patent/US10689399B2/en active Active
- 2018-08-17 LU LU00083C patent/LUC00083I2/en unknown
- 2018-08-21 LT LTPA2018511C patent/LTC2822954I2/lt unknown
- 2018-08-22 NL NL300947C patent/NL300947I2/nl unknown
- 2018-08-23 NO NO2018026C patent/NO2018026I2/no unknown
- 2018-08-23 CY CY2018022C patent/CY2018022I1/el unknown
- 2018-08-23 HU HUS1800035C patent/HUS1800035I1/hu unknown
- 2018-09-19 AU AU2018232957A patent/AU2018232957B2/en active Active
- 2018-09-26 JP JP2018179844A patent/JP6571256B2/ja active Active
-
2019
- 2019-02-22 ZA ZA2019/03516A patent/ZA201903516B/en unknown
- 2019-08-07 JP JP2019145317A patent/JP6933690B2/ja active Active
- 2019-10-29 HR HRP20191957TT patent/HRP20191957T1/hr unknown
- 2019-11-05 CY CY20191101151T patent/CY1122246T1/el unknown
-
2020
- 2020-05-01 AU AU2020202914A patent/AU2020202914B2/en active Active
- 2020-05-06 US US16/868,119 patent/US11548901B2/en active Active
- 2020-05-28 IL IL274988A patent/IL274988A/en unknown
-
2021
- 2021-08-19 JP JP2021134172A patent/JP7301918B2/ja active Active
- 2021-08-23 AU AU2021221427A patent/AU2021221427B2/en active Active
-
2023
- 2023-06-21 JP JP2023101636A patent/JP2023134483A/ja active Pending
- 2023-12-30 AU AU2023286038A patent/AU2023286038A1/en active Pending
-
2025
- 2025-06-04 JP JP2025093154A patent/JP2025138660A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016508134A5 (OSRAM) | ||
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| MX2024010140A (es) | Nuevos metodos. | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| JP2016515561A5 (OSRAM) | ||
| JP2016518337A5 (OSRAM) | ||
| NZ732391A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| JP2015038149A5 (OSRAM) | ||
| JP2016527217A5 (OSRAM) | ||
| JP2013518107A5 (OSRAM) | ||
| IL295418B1 (en) | Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus | |
| NZ735575A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| SI2932970T1 (en) | Antiviral therapy | |
| PH12015502539A1 (en) | Cenicriviroc compositions and methods of making and using the same | |
| JP2016034978A5 (OSRAM) | ||
| EA201391108A1 (ru) | Лечение липодистрофии | |
| JP2012255026A5 (OSRAM) | ||
| MX2015005949A (es) | Nucleosidos que contienen aza-azucar antiviral. | |
| WO2015148415A3 (en) | Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease | |
| NZ741957A (en) | Therapeutic compositions for treatment of human immunodeficiency virus | |
| PH12014500386A1 (en) | Combination treatment for hepatitis c | |
| JP2015532296A5 (OSRAM) | ||
| JP2015522018A5 (OSRAM) | ||
| JP2015516419A5 (OSRAM) |